Quarterly report · Q2
4574.TEDINET S100RMXK
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥5.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.9bn | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥396m | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | −¥2.4bn | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥510m | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥3.4bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.5bn | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥492m | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥514m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.9bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥514m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | −¥2.8bn | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥15.6bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥15.0bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥17.4bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.5bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.5bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.5bn | at 2021-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥126m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥631m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥707m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥190m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥96m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥827m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥997m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥501m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-11.36 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.76 | 2023-04-01 → 2023-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.26 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-64.17 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.05 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 58.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-01-01 → 2023-06-30 | ¥2m |
| Otherother segments | revenue external | 2023-01-01 → 2023-06-30 | ¥2m |
| Otherother segments | segment profit | 2023-01-01 → 2023-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-06-30 | −¥492m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥370m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥370m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥407m |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥2.1bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥514m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-06-30 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-06-30 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-06-30 | ¥95m |
| Otherother segments | revenue | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | revenue external | 2022-01-01 → 2022-06-30 | ¥4m |
| Otherother segments | segment profit | 2022-01-01 → 2022-06-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-01-01 → 2022-06-30 | −¥645m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥365m |
| jpcrp040300-q2r_E22560-000Infection Control Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥117m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-01-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-01-01 → 2022-06-30 | −¥1.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in operating activities | Prior1YTDDuration | -631000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 126000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -17000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -20000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 3000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 71000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -60000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -27000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -12000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -3000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 287000000 | JPY |
| Proceeds from redemption of investment securities inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from redemption of investment securities inv cf | CurrentYTDDuration | 400000000 | JPY |
| Purchase of investments in subsidiaries inv cf | Prior1YTDDuration | -9000000 | JPY |
| Purchase of investments in subsidiaries inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -96000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | 707000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -473000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -589000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -19000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -16000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -0 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -0 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYTDDuration | 1425000000 | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from issuance of subscription rights to shares fin cf | CurrentYTDDuration | 13000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -8000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -2000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -501000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 827000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 87000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 53000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1141000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 1714000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5521000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2797000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 4379000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4511000000 | JPY |
| Write downs of inventories | Prior1YTDDuration | 592000000 | JPY |
| Write downs of inventories | CurrentYTDDuration | 46000000 | JPY |
| Advertising expenses sga | Prior1YTDDuration | 219000000 | JPY |
| Advertising expenses sga | CurrentYTDDuration | 92000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 538000000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 386000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 7000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 33000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 38000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 22000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |